CTOs on the Move

OncoSec Medical

www.oncosec.com

 
OncoSec Medical Inc. is a biopharmaceutical company developing its ImmunoPulse immunotherapy to treat solid tumors. OncoSec Medical’s core technology leverages a proprietary electroporation platform to enhance the local delivery and uptake of DNA IL-12 and other DNA-based immune-modulating agents. Clinical studies of ImmunoPulse have demonstrated an acceptable safety profile and preliminary evidence of anti-tumor activity in the treatment of various skin cancers as well as the potential to initiate a systemic immune response without the systemic toxicities associated with other treatments. OncoSec’s clinical programs currently include three Phase 2 trials targeting metastatic melanoma Merkel cell carcinoma and cutaneous T-cell lymphoma ...
  • Number of Employees: 25-100
  • Annual Revenue: $50-100 Million
  • www.oncosec.com
  • 4690 Executive Dr Ste 250
    San Diego, CA USA 92121
  • Phone: 855.662.6732

Executives

Name Title Contact Details

Funding

OncoSec Medical raised $67.3M on 06/09/2015
OncoSec Medical raised $15M on 09/04/2018
OncoSec Medical raised $42M on 01/21/2021

Similar Companies

Kailos Genetics

Kailos Genetics, the maker of Praxis, provides consumers access to affordable physician-ordered genetic tests. It is our mission to help people take control of their health and make more informed decisions through identifying risks to common medications. Praxis is an easily accessible form of personalized medicine catered to your lifestyle.

Genemed Synthesis

Genemed Synthesis, Inc. is a San Antonio, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Fremont Analytical Inc

Fremont Analytical Inc is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Genetics Center

Genetics Center is a Orange, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Myriad

Myriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on three strategic imperatives: maintaining leadership in an expanding hereditary cancer market, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets.